Clinical Trial Update: Customized Choice of Oral P2Y12 Receptor Blocker [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating a customized choice of oral P2Y12 receptor blockers for patients with Acute Coronary Syndrome undergoing coronary angiopl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• BRILINTA (ticagrelor)
• CLOPIDOGREL (CLOPIDOGREL)
• EFFIENT (prasugrel hydrochloride)

Snippet

Sponsor: Italian Society of Invasive Cardiology | Conditions: Acute Coronary Syndrome, Coronary Angioplasty | Phase 4 | Status: UNKNOWN